Cite
Gut Microbes in Polycystic Ovary Syndrome and Associated Comorbidities; Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease (CVD), and the Potential of Microbial Therapeutics.
MLA
Singh, Vineet, et al. “Gut Microbes in Polycystic Ovary Syndrome and Associated Comorbidities; Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease (CVD), and the Potential of Microbial Therapeutics.” Probiotics and Antimicrobial Proteins, vol. 16, no. 5, Oct. 2024, pp. 1744–61. EBSCOhost, https://doi.org/10.1007/s12602-024-10262-y.
APA
Singh, V., Mahra, K., Jung, D., & Shin, J.-H. (2024). Gut Microbes in Polycystic Ovary Syndrome and Associated Comorbidities; Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease (CVD), and the Potential of Microbial Therapeutics. Probiotics and Antimicrobial Proteins, 16(5), 1744–1761. https://doi.org/10.1007/s12602-024-10262-y
Chicago
Singh, Vineet, Kanika Mahra, DaRyung Jung, and Jae-Ho Shin. 2024. “Gut Microbes in Polycystic Ovary Syndrome and Associated Comorbidities; Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease (CVD), and the Potential of Microbial Therapeutics.” Probiotics and Antimicrobial Proteins 16 (5): 1744–61. doi:10.1007/s12602-024-10262-y.